Issue 8/2024 Special Issue: Focus Issue on “Novel Antithrombotic Medications”
Content (9 Articles)
Novel antithrombotic approaches in cardiovascular disease – what is on the horizon?
- Direct Oral Anticoagulant
- Editorial
Geoffrey D. Barnes, Diana A. Gorog
The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease
- Open Access
- Hemophilia
Ahmed E. Ali, Richard C. Becker
Factor XIa inhibition as a therapeutic strategy for atherothrombosis
Eric Bailey, Renato D. Lopes, C. Michael Gibson, John W. Eikelboom, Sunil V. Rao
Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors
Anthony Dumas, Navneet Goyal, Madhusoodanan Mottamal, Daniel K. Afosah, Rami A. Al-Horani
Factor XI: structure, function and therapeutic inhibition
- Open Access
- Enoxaparin
Ahmed E. Ali, Richard C. Becker
Heparin-like effect of a dual antiplatelet and anticoagulant (APAC) agent on red blood cell deformability and aggregation in an experimental model
- Open Access
- Heparin
Adam Attila Matrai, Adam Varga, Barbara Bedocs-Barath, Erzsebet Vanyolos, Rita Orban-Kalmandi, Linda Loczi, Zsuzsa Bagoly, Annukka Jouppila, Riitta Lassila, Norbert Nemeth, Adam Deak
The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo
- Open Access
- Enoxaparin
Juergen Grafeneder, Gesche Langer, Christian Schoergenhofer, Farsad Eskandary, Bernd Jilma, Yasser Khder, Katarina D. Kovacevic Miljevic
RNAi targeting LMAN1-MCFD2 complex promotes anticoagulation in mice
- Open Access
- Anticoagulant
Siqian Ma, Boyan Liu, Hong Du, Fei Yang, Jingjing Han, Xinqi Huang, Minyang Zhang, Shundong Ji, Miao Jiang
The potential role of factor XI inhibitors in managing long COVID
- Long COVID Syndrome
- Letter to the Editor
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan, Kaeshaelya Thiruchelvam